Cannabis Poland (WAR:CBD) EBITDA Margin %: -4,270.59% (As of Mar. 2026)

What is Cannabis Poland EBITDA Margin %?

Cannabis Poland WAR:CBD 24 EBITDA Margin % is -4,270.59% as of Mar. 2026. GuruFocus rates WAR:CBD with a GF Score™ of 24/100. The stock has 7 warning signs investors should review. Among 952 Drug Manufacturers companies, Cannabis Poland ranks worse than 97.16% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cannabis Poland's EBITDA for the three months ended in Mar. 2026 was zł-0.73 Mil. Cannabis Poland's Revenue for the three months ended in Mar. 2026 was zł0.02 Mil. Therefore, Cannabis Poland's EBITDA margin for the quarter that ended in Mar. 2026 was -4,270.59%.

Cannabis Poland (WAR:CBD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cannabis Poland EBITDA Margin % Related Terms

Cannabis Poland EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Cannabis Poland's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Poland EBITDA Margin % Chart

Cannabis Poland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

-200.00

-318.00

-2,276.36

-864.80

-1,148.26

Cannabis Poland Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															-7,816.67	-5,685.71	-810.96	-555.88	-4,270.59

WAR:CBD vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Poland's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Poland EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Poland's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cannabis Poland's EBITDA Margin % falls into.

Save Embed

24GF Score

Cannabis Poland SA WAR:CBD

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cannabis Poland EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cannabis Poland's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-2.308	/	0.201
	=	-1,148.26 %

Cannabis Poland's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-0.726	/	0.017
	=	-4,270.59 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -4,270.59% mean?

Cannabis Poland (WAR:CBD) has a EBITDA Margin % of -4,270.59% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannabis Poland and its competitors. According to the industry distribution chart, Cannabis Poland ranks #925 out of 952 companies in the Drug Manufacturers industry, placing it in the top 97.2%.

Is Cannabis Poland's EBITDA Margin % too high?

Cannabis Poland's current EBITDA Margin % is -4,270.59%. Based on the distribution chart, Cannabis Poland ranks #925 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cannabis Poland has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.

How does Cannabis Poland's EBITDA Margin % compare to ZTS and UTHR?

According to the Drug Manufacturers industry distribution chart, Cannabis Poland ranks #925 out of 952 companies for EBITDA Margin %. This places Cannabis Poland in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Drug Manufacturers company?

The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannabis Poland and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Poland's current EBITDA Margin % is -4,270.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cannabis Poland stock overvalued right now?

Cannabis Poland (WAR:CBD) has a current EBITDA Margin % of -4,270.59%. The current EBITDA Margin % is -4,270.59%. Cannabis Poland's overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Cannabis Poland (WAR:CBD), the current EBITDA Margin % is -4,270.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Poland Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies WAR:MDB WAR:HMP WAR:BGD XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506

Other Exchanges 8TE:Germany

Address ul. Jana Styki 23, Warszawa, POL, 03-928

Website https://www.cp-sa.pl

Cannabis Poland SA is engaged in the business of cannabis, wherein it supplies plant products containing cannabinoids for pharmaceutical industry.

24GF Score

Get the complete analysis for WAR:CBD

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.20

Price

View WAR:CBD Analysis

See EBITDA Margin % data for all stocks →